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MicrotubulesAge-related neurodegenerative diseases are associated with alterations in gene expression in affected neurons.
One of the mechanisms that could account for this is altered subcellular localization of transcription factors,
which has been observed in human post-mortembrains of each of themajor neurodegenerative diseases, includ-
ing Parkinson's disease (PD). The speciﬁc mechanisms are yet to be elucidated; however a potential mechanism
involves alterations in nuclear transport. In this study, we examined the nucleocytoplasmic trafﬁcking of select
transcription factors in response to a PD-relevant oxidative injury, 6-hydroxydopamine (6OHDA). Utilizing a
well-established model of ligand-regulated nucleocytoplasmic shuttling, the glucocorticoid receptor, we found
that 6OHDA selectively impaired nuclear import through an oxidative mechanism without affecting nuclear
export or nuclear retention. Interestingly, impaired nuclear import was selective as Nrf2 (nuclear factor
E2-related factor 2) nuclear localization remained intact in 6OHDA-treated cells. Thus, oxidative stress speciﬁcally
impacts the subcellular localization of somebut not all transcription factors, which is consistentwith observations
in post-mortem PD brains. Our data further implicate a role for altered microtubule dependent trafﬁcking in the
differential effects of 6OHDA on transcription factor import. Oxidative disruption of microtubule-dependent
nuclear transport may contribute to selective declines in transcriptional responses of aging or diseased
dopaminergic cells.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Age-related neurodegenerative diseases, such as Parkinson's disease
(PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and
Huntington's disease (HD), are associated with alterations in expression
of speciﬁc genes in affected neurons [1–3]. Transcription factors play a
key role in the regulation of gene expression and the activity of many
transcription factors is limited by their localization within the cytoplasm.
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rights reserved.factors into the nucleus in response to speciﬁc signals [4–11]. Since
nucleocytoplasmic protein trafﬁcking can be bidirectional [12], transcrip-
tion factors exhibiting predominant nuclear localization may transit
through the cytoplasm and also function in nongenomic signaling net-
works [13–16]. Interestingly, alterations in the subcellular localization of
a number of transcription factors are documented in human post-
mortem brains of each of the major neurodegenerative diseases [5].
Examples include cytoplasmic aggregation of phosphorylated (p)CREB
(cAMP response element binding protein) and lack of nuclear pCREB
in PD [17], reduced nuclear localization of Nrf2 (nuclear factor E2-
related factor 2) in AD but not in PD [18], increased cytoplasmic ATF2
(activating transcription factor 2) levels in AD [19], and increased
cytoplasmic:nuclear ratios of TDP-43 (TAR DNA-binding protein 43)
in frontotemporal lobar dementias and ALS [20].
Extensive evidence of oxidative damage to proteins, lipids, and DNA
is found upon analysis of post-mortem brains of various neurodegener-
ative diseases, including PD [21–31]. Furthermore, genetic and environ-
mental models of various neurodegenerative diseases support the
notion that oxidative stress plays a primary role in their pathogenesis
[24–26]. In the case of PD, mutations or deﬁciency of proteins such as
Parkin, PINK1 (PTEN-induced putative kinase 1), α-synuclein, DJ-1,
and LRRK2 (leucine-rich repeat kinase 2), have been shown to increase
susceptibility to oxidative stress-mediated cell death [32–34]. Parkinso-
nian mimetics such as, 6-hydroxydopamine (6OHDA), 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat,
generate reactive oxygen species (ROS) and cause neuronal death
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genesis of these diseases.
6OHDA has been widely used to study neuronal injury responses
in PD. It is an analog of catecholamine neurotransmitters that is
taken up into cells by dopamine and norepinephrine reuptake trans-
porters. It is commonly used to model PD-relevant oxidative stress
as it demonstrates an early autoxidation phase of ROS production
and also has a delayed phase of mitochondrial ROS production [36].
Although used as an exogenous neurotoxin, there is evidence of spon-
taneous ring hydroxylation of dopamine in vivo, with elevated body
ﬂuid levels of 6OHDA detected in patients treated with L-Dopa [37,38].
6OHDA treatment leads to increased cytoplasmic accumulation of (p)
ERK (extracellular signal-regulated kinase) [39] and decreased nuclear
levels of GFP (green ﬂuorescent protein)-ERK2 [40], as well as decreasing
thenuclear to cytoplasmic ratios of pCREB in SH-SY5Y cells and inprimary
midbrain neurons [17]. These ﬁndings are consistent with alterations
observed in dopaminergic neurons in post-mortem PD brains [5]. CREB-
regulated gene transcription, which is important for axon growth, mi-
tochondrial biogenesis, and neuronal survival, was also repressed in
6OHDA treated cells. Given the dynamic shuttling of transcription factors
between the nuclear and cytoplasmic compartments, there are a number
of mechanisms that could result in altered distribution of transcription
factors in degenerating neurons, including compartmentalization, altered
expression levels, sequestration in protein aggregates, and nuclear trans-
port deﬁcits [5]. Interestingly, 6OHDA impairment of CREB-mediated
transcription (e.g. Bcl2 [B-cell lymphoma 2] and BDNF [brain-derived
neurotrophic factor])was reversedwith cAMP treatment, which activates
CREB through mechanisms not requiring active nuclear import [17,41]—
suggesting a possible impairment in the nucleocytoplasmic trafﬁcking
of CREB. The observed steady state alterations in the distribution of
transcription factors could result from altered nuclear import/export
with signiﬁcant consequences on neuronal survival. The main goal of
this study was to directly examine, in a neuronal cell line, the impact
of 6OHDA-induced oxidative stress on distinct steps in the regulated
nucleocytoplasmic trafﬁcking of select transcription factors.
2. Materials and methods
2.1. Cell culture
SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA) were grown
on 10 cm cell culture dishes containing Dulbecco's Modiﬁed Eagle's
Medium (DMEM) with 10% heat-inactivated fetal calf serum, 2 mM
L-glutamine, and 10 mM HEPES. Cells were maintained at 37 °C in a
humidiﬁed 5% CO2 incubator.
2.2. Plasmids and transfections
SH-SY5Y cells were transfected with Lipofectamine™ 2000 reagent
(Invitrogen, Carlsbad, CA) utilizing Opti-MEM® I reduced serum media
(Invitrogen, Carlsbad, CA) according to the manufacturer's protocol at a
ﬁnal Lipofectamine concentration of 0.1%. Cells were grown for at least
48 h before transfection and then allowed to express the protein of inter-
est for another 24 h–48 h before treatment. GR-GFP and Nrf2-GFP plas-
mids were kindly provided by Dr. Ian Macara (University of Virginia)
and Dr. Manabu Furukawa (University of Nebraska), respectively.
2.3. Drug treatments
6OHDA (Sigma, St. Louis, MO)was prepared in cold sterile water im-
mediately before use. Dexamethasone (Sigma), a synthetic glucocorti-
coid hormone, was prepared at a stock concentration of 10−3 M in
95% EtOH and used at a working concentration of 10−6 M unless other-
wise stated. Cortisol (Sigma) was prepared at a stock concentration of
10−3 M to 10−4 M in 100% EtOH and used at a working concentration
of 10−6 M to 10−7 Munless otherwise stated. For antioxidant treatment,a metalloporphyrin antioxidant, MnTBAP (A.G. Scientiﬁc, San Diego, CA),
was utilized at a ﬁnal concentration of 150 μM. Colchicine (Sigma) and
Paclitaxel (Sigma) were prepared in dH2O and DMSO, respectively, and
used at the concentrations indicated in the text.
2.4. Monomeric tubulin extraction
Cells treatedwith either vehicle or the drug of interestwerewashed in
37 °C DPBS (Dulbecco's Phosphate-Buffered Saline) and then incubated
with tubulin extraction buffer (10 mM PIPES, pH 6.8, 50 mM KCl, 2 mM
EGTA, 1 mMMgCl2, 2 M glycerol, 0.5% Triton X-100, 1 mM Na3VO4, and
protease inhibitor cocktail [Sigma]) for 15 min at room temperature.
The resulting lysate was then centrifuged at 37 °C at 16,000×g for
2 min to pellet any polymerizedmicrotubules. The resulting supernatant,
containing soluble (monomeric) tubulin, was then subjected to Western
blotting. The protocol was modiﬁed from [42].
2.5. Immunoblotting
Cell extracts were collected and immunoblotswere performed as pre-
viously described [43] with the following exception: BioRad (Hercules,
CA) gel running systemwith a 10% gel was used to separate proteins. Pri-
mary antibodies used: anti-α-tubulin (1:5000; Sigma) and anti-GAPDH
(1:10,000; Abcam). ImageJ (NIH) was utilized for densitometry (from
N≥3 experiments).
2.6. Cell toxicity assay
Cells were plated in 96-well plates and treated with 150 μM
6OHDA for varying amounts of time. LDH (lactate dehydrogenase)
release assay was carried out according to the protocol provided by
the manufacturer (Promega, Madison, WI). Spectramax M2 plate
reader was utilized to read the ﬂuorescent signal (Molecular Devices,
Sunnyvale, CA). Percent cytotoxicity was calculated by the following
formula: 100×[(Experimental−Medium Background)/(Maximum
LDH release−Medium Background)]. Maximum LDH release was
determined by treatment of cells with lysis buffer as permanufacturer's
protocol.
2.7. Quantitative image analysis and statistics
An inverted epiﬂuorescent microscope (Olympus IX71) was
used for imaging and ImageJ was utilized for quantiﬁcation. Nucle-
ar:cytoplasmic ratios were calculated from at least 50 randomly imaged
cells per experiment (and pooled from at least three independent
experiments) bymeasuring the ﬂuorescent intensitywithin a randomly
distributed region of interest of ﬁxed size within the nuclear and the
cytoplasmic compartments. Raw ﬂuorescent intensity is shown in
the ﬁgures. Nrf2 distribution was also scored into two categories:
(1) cytoplasmic and (2) cytoplasmic and nuclear. Example images of
these categories are shown in the Results section. Student's t test was
used to compare means between two groups. One-way analysis of
variance (ANOVA) followed by posthoc Tukey HSD test was used for
multiple comparisons. A p-valueb0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Subcellular localization of GR in response to hormone
The glucocorticoid receptor (GR) was used to examine the effects of
6OHDA-induced oxidative stress on bidirectional nucleocytoplasmic
trafﬁcking. Transport of GR from the cytoplasm to the nucleus is
hormone-dependent and bidirectional as hormone withdrawal triggers
its export from the nucleus [12,44–46]. Therefore, both steps in the
nucleocytoplasmic trafﬁcking of this transcription factor are regulated
Fig. 1. Dexamethasone and cortisol induce GR nuclear import. SH-SY5Y cells express-
ing GR-GFP were treated for 1 h with Dex or Cort at the indicated concentrations. In
the absence of either ligand, GR-GFP is cytoplasmic in the majority of the cells
(~60%) with the remainder showing some nuclear localization as well. The raw mean
ﬂuorescent intensity within equal size nuclear and cytoplasmic regions (N/C ratio)
for untreated cells is approximately 1. After hormone treatment, GR-GFP is primarily
localized within the nucleus. Nuclear:cytoplasmic GR-GFP ratios were determined as
noted in the Materials and methods section. Representative images from Dex treat-
ment are shown. Mean+/−SEM, *pb0.05 vs. Veh. Cont. Compiled from 3 independent
experiments.
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cells were transfected with an expression vector for GR-GFP and treated
for 1 h with either Dexamethasone (Dex), a synthetic glucocorticoid, or
Cortisol (Cort), the primary circulating glucocorticoid in humans. In the
absence of Dex or Cort, GR-GFP is cytoplasmic in themajority of the cells
(~60% on average) with the remainder of cells also showing someFig. 2. 6OHDA reduces GR nuclear import. (A) LDH release assay showed no evidence of toxic
GR-GFP expressing SH-SY5Y cells were exposed to 150 μM 6OHDA for 1 h and 4 h and the
observed in 6OHDA-treated cells. Mean+/−SEM, *pb0.05 vs. No Ligand; #pb0.05 vs. Veh.nuclear localization. The mean ﬂuorescent intensity within equal size
nuclear and cytoplasmic regions (nuclear:cytoplasmic ratio) for
untreated cells is on average around 1 (Fig. 1). A dose-dependent in-
crease in nuclear transport of GR-GFP was observed with a signiﬁcant
nuclear localization attained at ≥10−7 M Dex or Cort (Fig. 1).3.2. 6OHDA treatment impairs nuclear import of GR
With 150 μM 6OHDA (dose where impaired CREB/pCREB localiza-
tion is observed [17]), treatment for less than 6 h did not cause cell
death (Fig. 2A). To determine if 6OHDA treatment causes an impairment
in nuclear import, GR-GFP expressing SH-SY5Y cells were ﬁrst treated
with 150 μM 6OHDA for 1 h and 4 h and then treated with 1 μM Dex
for 1 h to induce the nuclear localization of GR-GFP. As seen in Fig. 2B
and C, pre-treatment with 6OHDA impaired the hormone-dependent
nuclear import of GR-GFP. Signiﬁcant reduction in the extent of nuclear
import was also seen at doses varying from 90 μM to 300 μM and treat-
ment times as early as 30 min (data not shown).3.3. Antioxidant treatment reverses 6OHDA-induced impairment in nu-
clear import
6OHDA has the propensity to produce free radicals [36,47]. To de-
termine whether the nuclear import impairment observed in 6OHDA-
treated cells involves oxidative stress, SH-SY5Y cells expressing GR-
GFP were treated with MnTBAP, a cell permeable SOD mimetic,
30 min before or 30 min after the start of 6OHDA treatment (150 μM;
4 h) (Fig. 3). When cells were treated with MnTBAP before being
exposed to 6OHDA, a near complete rescue in GR-GFP nuclear import
was observed (Fig. 3A). When cells were ﬁrst treated with 6OHDA for
30 min before the addition of MnTBAP, a partial protection was ob-
served (Fig. 3B). This is consistent with the observation that 6OHDA
treatment as short as 30 min is enough to cause some impairment in
GR nuclear import (data not shown). The rescue observedwithMnTBAP
treatment suggests that an oxidative mechanism is responsible at least
in part for the 6OHDA-mediated reduction in GR nuclear import.ity until 6 h of 6OHDA treatment (150 μM). Mean+/−SEM, *pb0.05 vs. Cont. (B and C)
n treated with 1 μM Dex for an additional 1 h. Signiﬁcant reduction in GR import was
Cont. Compiled from 3 independent experiments.
Fig. 3. MnTBAP rescues 6OHDA-induced impairment in GR nuclear import. SH-SY5Y
cells expressing GR-GFP were treated with MnTBAP, a cell permeable SOD mimetic,
30 min before (A) and 30 min after (B) the start of 6OHDA treatment (150 μM for
4 h). A complete and a partial protection was observed with pre- and post-6OHDA
treatments with MnTBAP, respectively. Mean+/−SEM, *pb0.05. Compiled from 3 in-
dependent experiments.
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In addition to impaired nuclear import, enhanced nuclear export
could also explain the altered transcription factor distribution observed
in neurodegenerative diseases. To study if nuclear export is affected
by 6OHDA-induced oxidative stress, a hormone withdrawal study wasFig. 4. 6OHDA does not alter GR nuclear export. SH-SY5Y cells expressing GR-GFP were tre
vehicle or 6OHDA for up to 4 h. No signiﬁcant change in nuclear export of GR-GFP was obs
experiments.performed in SH-SY5Y cells expressing GR-GFP. Cort, the naturally oc-
curring ligand for GR, dissociates rapidly fromGR and is therefore better
suited for studying the effects of hormonewithdrawal [46,48]. SH-SY5Y
cells expressing GR-GFP were ﬁrst treated with 10−7 M Cort for 1 h to
induce the nuclear localization of GR-GFP. The cells were then with-
drawn from the ligand for up to 4 h in the presence of either vehicle
or 150 μM 6OHDA. No signiﬁcant change in nuclear export of GR-GFP
was observed in cells exposed to 6OHDA compared to vehicle control
(Fig. 4).
3.5. 6OHDA does not alter GR nuclear retention
6OHDA-induced oxidative stress could damage the nuclear envelope
or chromatin binding sites and therefore alter nuclear retention of GR.
To investigate this possibility, SH-SY5Y cells expressing GR-GFP were
ﬁrst treated with Dex for 1 h to fully induce the nuclear translocation
of GR-GFP and then exposed to 150 μM of 6OHDA from 2 to 6 h in the
presence of Dex (Fig. 5). If 6OHDA-induced oxidative stress damaged
the nuclear envelope or reduced GR binding to high afﬁnity chromatin
binding sites, an increase in ligand-bound cytoplasmic GR-GFP could
occur. However, no signiﬁcant change in subcellular localization was
observed—suggesting that 6OHDA does not reduce GR-GFP nuclear re-
tention or trigger its leakage from a “damaged” nucleus. In combination
with the results of GRnuclear import andexport assays, our data suggest
that 6OHDA-induced oxidative stress impairs the hormone-dependent
nuclear import of GR.
3.6. Nrf2 translocates into the nucleus in response to 6OHDA
One of the transcription factors that did not show reduced nuclear
localization in post-mortem human PD brains is Nrf2, a key protein in
the defense against cellular stresses. Under basal metabolic conditions,
Nrf2 is sequestered in the cytoplasm and targeted for proteasomal degra-
dation via its association with Keap1 (kelch-like ECH-associated protein
1). Upon exposure to ROS, electrophiles, or serum factors, Nrf2 dissociates
from the Keap1 inhibitory complex and translocates into the nucleus,
where it upregulates stress response genes and protects against neuro-
toxic insults [49–55]. For this reason, studies of Nrf2 nuclear translocation
typically involve pre-incubation under serum-deprived conditions to shift
the basal distribution of Nrf2 toward the cytoplasm [54,56]. SH-SY5Y cells
expressing Nrf2-GFP exhibited reduced nuclear:cytoplasmic ratios when
grown in low-serum media (1% FBS) for 24 h (Fig. 6A). Serum depriva-
tion also caused an increase in the percentage of cells with cytoplasmicated with 10−7 M Cort for 1 h and then withdrawn from the ligand in the presence of
erved in 6OHDA treated cells. Mean+/−SEM, p>0.05. Compiled from 3 independent
Fig. 5. 6OHDA does not alter GR nuclear retention. SH-SY5Y cells expressing GR-GFP
were ﬁrst treated with Dex for 1 h and then exposed to 150 μM of 6OHDA from 2 to
6 h in the presence of Dex. No signiﬁcant change in nuclear retention of GR-GFP was
observed. Mean+/−SEM, p>0.05. Compiled from 3 independent experiments.
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cytoplasmic and nuclear localization (Fig. 6B).
Nrf2 nuclear localization in response to 6OHDA-induced oxidative
stress was then studied. Serum deprived SH-SY5Y cells expressing
Nrf2-GFP were treated with increasing doses of 6OHDA (from 30 μM
to 150 μM),which caused a progressive increase in the nuclear localiza-
tion of Nrf2. The results from cells treated with 150 μM 6OHDA are
shown in Fig. 6C. Quantitation of Nrf2-GFP localization revealed a de-
crease in the percentage of cells showing predominant cytoplasmic lo-
calization and an increase in the percentage of cells showing both
cytoplasmic and nuclear Nrf2 localization(Fig. 6D). These results areFig. 6. 6OHDA induces Nrf2 nuclear localization. (A and B) Standard culture conditions elicit
media (1% FBS) for 24 h and nuclear localization was quantiﬁed by two methods as describe
Nrf2-GFP or cytoplasmic+nuclear Nrf2-GFP are shown. Mean+/−SEM, *pb0.05 vs. 10% FBS
increased nuclear and a decreased cytoplasmic localization of Nrf2-GFP. Mean+/−SEM, *psimilar to the studies examining Nrf2 nuclear translocation in response
to H2O2 treatment [54]. Thus, inhibitory effects of 6OHDA on nuclear
transport are selective and inﬂuence the active nuclear import of GR
but not of Nrf2.
3.7. 6OHDA increases levels of unpolymerized tubulin
The nucleocytoplasmic trafﬁcking of some transcription factors,
including CREB [57] and GR [58,59], is dependent on microtubules
(MTs) in some cells. Hence, alterations in MT function due to 6OHDA-
induced oxidative stress could help explain the selective trafﬁcking
impairments. This is of particular relevance given the alterations in MT
function observed in several age-related neurodegenerative diseases
[60,61]. In the case of PD, both toxin (e.g. MPP+and rotenone) and
genetic (e.g. α-synuclein and LRRK2) models implicate impaired MT
function as a common pathway of neuronal degeneration [62–65].
We investigated the effects of 6OHDA-induced oxidative stress on po-
lymerization of tubulin. We ﬁrst determined the effects of MT-altering
agents, colchicine and paclitaxel, on the levels of unpolymerized tubulin
(Fig. 7A). SH-SY5Y cells were treated with either vehicle, 1 μM colchicine
(2 h), or 50 nM paclitaxel (1 h) and then incubated with tubulin extrac-
tion buffer to extract monomeric tubulin. Colchicine increased and pacli-
taxel reduced the levels of monomeric tubulin, respectively, while not
signiﬁcantly affecting the levels of total tubulin (Fig. 7A andB). These con-
centrations of MT-altering agents did not cause cell death (data not
shown). We then examined the effects of 6OHDA on the levels of unpo-
lymerized tubulin. SH-SY5Y cells were treated with 150 μM 6OHDA
from1 h to 4 h afterwhichmonomeric tubulinwas extracted. Cells treat-
ed with 6OHDA showed increased levels of monomeric tubulin (Fig. 7C).
Levels of total tubulin were not altered in 6OHDA-treated cells (Fig. 7D).Nrf2 nuclear translocation. To desaturate the assay, cells were incubated in low serum
d in the Materials and methods section. Example images of cells scored as cytoplasmic
. (C and D) Treatment of serum deprived SH-SY5Y cells with 150 μM 6OHDA caused an
b0.05 vs. Veh. Cont. Compiled from 3 independent experiments.
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Wethen examined theeffects of directlymodulatingMTs on the traf-
ﬁcking of GR and Nrf2. Colchicine and paclitaxel were utilized to disrupt
or stabilize, respectively, the MT network in SH-SY5Y cells expressing
GR-GFP and Nrf2-GFP (Fig. 8). SH-SY5Y cells expressing GR-GFP were
exposed to these agents at doses and times indicated above and then
treated with Cort to induce the nuclear translocation of GR-GFP. MT sta-
bilization using paclitaxel did not alter the nuclear import of GR-GFP,
however a decrease in nuclear import was observed in cells where the
MT network was disrupted by colchicine treatment (Fig. 8A). Neither
MT stabilization nor disruption signiﬁcantly impaired Nrf2-GFP subcel-
lular localization compared to vehicle in response to 6OHDA stress
(Fig. 8B). Thus, the effect of 6OHDA on MT stability was similar to that
of colchicine, and colchicine recapitulated the selective nuclear import
impairment elicited by 6OHDA.
4. Discussion
In this study, we examined the effects of 6OHDA on the nucleocy-
toplasmic trafﬁcking of two transcription factors that are sequestered
in the cytoplasm, but utilize distinct mechanisms for release from cy-
toplasmic anchors and import into the nucleus. Previously published
work has demonstrated adverse functional effects of altered pCREB
or pERK2 subcellular localization onmidbrain dopaminergic neuron sur-
vival [17,39], but the mechanism underlying such localization changes
remained unclear. Utilizing awell-establishedmodel of regulated nucle-
ar transport, the glucocorticoid receptor, we found that 6OHDA treat-
ment elicited early impairments in nuclear import without causing
reduced nuclear retention or enhanced nuclear export. Treatment with
an antioxidant rescued the defect in GR nuclear import, supporting an
oxidative mechanism for the 6OHDA-induced effects.
While relatively high doses of H2O2 and other oxidants can affect
nuclear transport through global mechanisms in non-neuronal cells
[10,66–72], the effects of sublethal/prelethal oxidative stress have not
been previously studied in neuronal cells. Interestingly, the impaired
nuclear import observed in our system did not result from global nucle-
ar import failure asNrf2 nuclear localization remained intact in 6OHDA-
treated cells. The selective nature of these effects suggests a speciﬁc
alteration that impacts the subcellular localization of some but not all
transcription factors. Our in vitro results are consistent with observa-
tions that Nrf2 shows clear nuclear localization in post-mortem PD
substantia nigra neurons [18], while kinases and transcription factors
activated by trophic signals show abnormal cytoplasmic accumulation
[5]. These ﬁndings suggest that the impaired neurotrophic response
may outweigh the intact antioxidant response after oxidative injury,
leading to neuronal degeneration.
Interestingly, GR has been linked to the regulation of the dopaminer-
gic system, including through its interactions with the nuclear receptor
related 1 protein (Nurr1)—which is important for dopaminergic differ-
entiation and phenotype maintenance as well as being associated with
PD [73–83]. Furthermore, glucocorticoids have been shown to play a
protective role in models of PD, although the mechanisms may involve
more than one cell type in the brain [74,77]. In any case, selective im-
pairment of a subset of transcription factors in the aging or oxidatively
stressed brainmay account for downregulation of dopaminergic differen-
tiation markers observed in PD models [84–90] and for alterations in
neurotrophic gene expression observed in PDmidbrain tissues [1,91–94].Fig. 7. 6OHDA increases levels of unpolymerized tubulin. (A) SH-SY5Y cells were treated w
with tubulin extraction buffer to extract monomeric tubulin and resolved by Western blottin
tively. Mean+/−SEM, *pb0.05 vs. Veh. Cont. (B) Whole cell extracts of colchicine and pac
changes in total tubulin levels. Mean+/−SEM, p>0.05 vs. Veh. Cont. (C) SH-SY5Y cells w
extracted. 6OHDA-induced oxidative stress increased the levels of monomeric tubulin. M
were subjected to Western blotting, which showed no changes in total tubulin levels. Mea
from 3 independent experiments.Themechanism(s) underlying the selectivity in nuclear trafﬁcking of
proteins observed in this model of parkinsonian injury and in diseased
PD brains may be of particular relevance to chronic neurodegeneration.
Since not all transcription factors are affected, a global mechanism that
would impair all nuclear transport, such as bioenergetic collapse, is un-
likely. This is further supported by the early time points at which the
trafﬁcking impairment becomes apparent. The current data implicate a
role for altered microtubule dependent trafﬁcking. Some transcription
factors utilize MTs for their transport. Indeed, a sequence within the
parathyroid hormone related protein was recently found to efﬁciently
transport fusion proteins into the nucleus via a MT facilitated “fast
track” mechanism [95]. Oxidative stress (e.g. H2O2) has been linked to
impaired MT function, such as decreased tubulin polymerization rate
and MT growth rate [96–99]. In our model, we found that 6OHDA in-
creased the levels of free monomeric tubulin similar to colchicine,
suggesting enhanced depolymerization and/or reduced polymerization.
Furthermore, colchicine-mediated disruption but not stabilization of
MTs mimicked the effects of 6OHDA in reducing nuclear import of GR
without affecting Nrf2 import. These results suggest that 6OHDAmodu-
lates transcription factor trafﬁcking through effects on MT-dependent
transport of transcription factors.
How could 6OHDA-induced oxidative stress affect the state of tu-
bulin polymerization? A possible mechanism is through the direct ox-
idative modiﬁcation of the tubulin heterodimer, which has numerous
cysteine residues. Oxidation of cysteine residues has been shown to
reduce tubulin polymerization rate andhence could explain the increased
levels of unpolymerized tubulin after 6OHDA treatment [100–102]. Fur-
thermore, rates of tubulin polymerization and depolymerization are also
regulated by microtubule-associated proteins (MAPs) and the binding
of these proteins to MTs could be directly regulated by oxidative modiﬁ-
cations [98,103–105]. The binding of MAPs to MTs is also regulated by
tubulin post-translational modiﬁcations (PTMs), such as acetylation,
tyrosination/detyrosination, and polyglutamylation [106,107]. Modula-
tion of tubulin PTMs by oxidative stress therefore represents another
means bywhich 6OHDA could impact the state of tubulin polymerization.
In addition to altered MT dynamics, there are other potential mecha-
nisms that could contribute to selective impairments in nuclear transport.
Oxidative injury, e.g. H2O2, has been shown to alter the distribution of the
small G protein Ran, which is a key player in the classic import/export
cycle [68,70,71,108]. Although such an alteration would be expected to
affect nuclear transport ofmany proteins, it is possible that different tran-
scription factors have differential sensitivity to the breakdown of the Ran
gradient across the nucleus or utilize an alternative non-Ran dependent
mechanism for their nuclear import [11,109]. Another possibility is the
involvement of carrier proteins for nuclear import, importins. Different
transcription factors utilize different importins for their nuclear import,
as is the case for CREB, GR, and Nrf2—hence oxidative stress-induced
alterations in different importins could also help explain the observed
selectivity [110–112]. Evidence of altered levels or localization of speciﬁc
importins has been described in various neurodegenerative diseases [10].
In summary, we have found that 6OHDA selectively impairs nuclear
import through an oxidative mechanism that may involve alterations in
MT-dependent trafﬁcking of transcription factors. Given the importance
of transcription factors for regulating gene expression, alterations in
their nucleocytoplasmic transport could have signiﬁcant consequences
for neuronal differentiation, function, and survival. For chronic diseases
such as PD, oxidative stress related to aging, the cellular handling of the
oxidative catecholamine neurotransmitters, or mitochondrial pathologyith either vehicle, 1 μM colchicine (2 h), or 50 nM paclitaxel (1 h) and then incubated
g. Colchicine increased and paclitaxel reduced the levels of monomeric tubulin, respec-
litaxel treated cells were subjected to Western blotting, which showed no signiﬁcant
ere treated with 150 μM 6OHDA for 1 h and 4 h after which monomeric tubulin was
ean+/−SEM, *pb0.05 vs. Veh. Cont. (D) Whole cell extracts of 6OHDA-treated cells
n+/−SEM, p>0.05 vs. Veh. Cont. Western blot results were quantiﬁed and compiled
Fig. 8. MTs regulate GR but not Nrf2 nuclear trafﬁcking. (A) GR-GFP expressing SH-SY5Y
cells were treated with either paclitaxel or colchicine and then treated with Cort for
30 min to induce GR-GFP nuclear import. Reduced GR-GFP nuclear import was observed
in colchicine treated cells but not in paclitaxel treated cells. Mean+/−SEM, *pb0.05 vs.
Veh. Cont. (B) Nrf2-GFP expressing SH-SY5Y cells were treated with either paclitaxel or
colchicine and then treated with 150 μM 6OHDA for 30 min to induce Nrf2-GFP nuclear
localization. No signiﬁcant impairment was observed with either MT-altering agent.
Mean+/−SEM, p>0.05 vs. Veh. Cont. Compiled from 3 independent experiments.
1780 V.P. Patel et al. / Biochimica et Biophysica Acta 1822 (2012) 1773–1782could contribute to reduced trophic and reparative transcriptional
responses through selective impairments in nuclear import.
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